{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T20:01:29Z","timestamp":1784577689489,"version":"3.55.0"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"DOI":"10.1186\/s40164-026-00802-3","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T06:13:11Z","timestamp":1784527991000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Optimizing the timing of JAK1 inhibition preserves the anti-tumor efficacy of radioimmunotherapy in lung cancer by preventing T cell exhaustion"],"prefix":"10.1186","volume":"15","author":[{"given":"Zhiru","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"issue":"5","key":"802_CR1","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","volume":"77","author":"S Banerjee","year":"2017","unstructured":"Banerjee S, Biehl A, Gadina M, Hasni S, Schwartz DM. JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects. Drugs. 2017;77(5):521\u201346.","journal-title":"Drugs"},{"issue":"6702","key":"802_CR2","doi-asserted-by":"publisher","DOI":"10.1126\/science.adf1329","volume":"384","author":"D Mathew","year":"2024","unstructured":"Mathew D, Marmarelis ME, Foley C, Bauml JM, Ye D, Ghinnagow R, et al. Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients. Science. 2024;384(6702):eadf1329.","journal-title":"Science"},{"issue":"1","key":"802_CR3","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S1470-2045(23)00589-2","volume":"25","author":"Y Song","year":"2024","unstructured":"Song Y, Malpica L, Cai Q, Zhao W, Zhou K, Wu J, et al. Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study. Lancet Oncol. 2024;25(1):117\u201325.","journal-title":"Lancet Oncol"},{"issue":"19","key":"802_CR4","doi-asserted-by":"publisher","first-page":"13317","DOI":"10.1021\/jacs.4c01720","volume":"146","author":"E Rafic","year":"2024","unstructured":"Rafic E, Ma C, Shih BB, Miller H, Yuste R, Palomero T, et al. Ru Bi-Ruxolitinib: a photoreleasable antitumor JAK inhibitor. J Am Chem Soc. 2024;146(19):13317\u201325.","journal-title":"J Am Chem Soc"},{"issue":"4","key":"802_CR5","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.3892\/ol.2017.6690","volume":"14","author":"D Liu","year":"2017","unstructured":"Liu D, Huang Y, Zhang L, Liang DN, Li L. Activation of Janus kinase 1 confers poor prognosis in patients with non-small cell lung cancer. Oncol Lett. 2017;14(4):3959\u201366.","journal-title":"Oncol Lett"},{"issue":"4","key":"802_CR6","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","volume":"15","author":"DE Johnson","year":"2018","unstructured":"Johnson DE, O\u2019Keefe RA, Grandis JR. Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018;15(4):234\u201348.","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"802_CR7","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/s41584-024-01153-1","volume":"20","author":"A Virtanen","year":"2024","unstructured":"Virtanen A, Spinelli FR, Telliez JB, O\u2019Shea JJ, Silvennoinen O, Gadina M. JAK inhibitor selectivity: new opportunities, better drugs? Nat Rev Rheumatol. 2024;20(10):649\u201365.","journal-title":"Nat Rev Rheumatol"},{"key":"802_CR8","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s40164-024-00543-1","volume":"13","author":"S Zheng","year":"2024","unstructured":"Zheng S, Wang W, Shen L, Yao Y, Xia W, Ni C. Tumor battlefield within inflamed, excluded or desert immune phenotypes: the mechanisms and strategies. Exp Hematol Oncol. 2024;13:80.","journal-title":"Exp Hematol Oncol"},{"key":"802_CR9","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s40164-024-00539-x","volume":"13","author":"Y Yin","year":"2024","unstructured":"Yin Y, Feng W, Chen J, Chen X, Wang G, Wang S, et al. Immunosuppressive tumor microenvironment in the progression, metastasis, and therapy of hepatocellular carcinoma: from bench to bedside. Exp Hematol Oncol. 2024;13:72.","journal-title":"Exp Hematol Oncol"}],"container-title":["Experimental Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-026-00802-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-026-00802-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-026-00802-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T19:01:52Z","timestamp":1784574112000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40164-026-00802-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":9,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["802"],"URL":"https:\/\/doi.org\/10.1186\/s40164-026-00802-3","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"25 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All studies involving animals were conducted according to the guidelines approved by Institutional Animal Care and Use Committees (IACUC) and the standard and local regulatory requirements.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors give their consent to publish this manuscript.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"62"}}